Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Bedke, Jens and Rini, Brian I. and Plimack, Elizabeth R. and Stus, V. and Gafanov, Rustem and Waddell, Tom and Nosov, D. and Pouliot, Frédéric and Soulières, D. and Melichar, B. and Vynnychenko, I. and Azevedo, Sergio Jobim and Borchiellini, Delphine and McDermott, Raymond S. and Tamada, Satoshi and Nguyen, Allison Martin and Wang, S. (2021) Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. EUROPEAN UROLOGY, 82 (4). pp. 427-439. ISSN ISSN : 0302-2838

Other Health-related....PDF Download (420kB)

Abstract

The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma.

Item Type:	Article
Additional Information:	DOI: 10.1016/j.eururo.2022.06.009
Uncontrolled Keywords:	Advanced renal cell carcinoma; Axitinib; Health-related quality of life; Pembrolizumab; Sunitinib.
Subjects:	Urology Oncology
Divisions:	Departments > Department of Urology
Depositing User:	Аліна Чеботарьова
Date Deposited:	08 Nov 2022 12:31
Last Modified:	08 Nov 2022 12:31
URI:	http://repo.dma.dp.ua/id/eprint/7910

Actions (login required)

View Item